Clinical Supply Licensing Treatment 
The Pharma Data
JANUARY 10, 2021
Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development. In July 2020, the U.S.
The Pharma Data
NOVEMBER 22, 2020
MP0420 is subject to an option and license agreement with Novartis AG to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program. MP0420 is designed to bind the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein at three distinct locations to prevent viral entry into cells.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
AUGUST 15, 2021
Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. VTX-801 is a novel investigational gene therapy to be evaluated in a Phase 1/2 clinical trial to determine the safety, tolerability, and pharmacological activity of a single intravenous infusion in adult patients with Wilson Disease.
The Pharma Data
OCTOBER 27, 2020
Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19. During the clinical development stage, Molecular Partners will provide clinical supply.
The Pharma Data
JANUARY 24, 2021
Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases. Food and Drug Administration (“FDA”) approval. PharmaDrug Inc.
BioPharma Drive: Drug Pricing
JUNE 9, 2025
Originally designed to regulate blood sugar in type 2 diabetes, GLP-1 receptor agonists have evolved into groundbreaking treatments for obesity, cardiovascular disease and even neurodegenerative conditions. As more people take them and their uses grow, so does their potential.
BioPharma Drive: Drug Pricing
JUNE 9, 2025
From pioneering treatments for rare pediatric diseases to exploring natural killer cells for Alzheimers and developing FDA-approved digital therapeutics for fibromyalgia, each episode reveals the scientific ingenuity and personal determination behind medical advances. 1 Pioneering Treatments for Rare Pediatric Diseases Ep.
Expert insights. Personalized for you.
Let's personalize your content